LncRNA GAS5 enhances tumor stem cell-like medicated sensitivity of paclitaxel and inhibits epithelial-to-mesenchymal transition by targeting the miR-18a-5p/STK4 pathway in prostate cancer Lu TT, Tao X, Li HL, Gai L, Huang H, Li F, - Asian J Androl

Users Online:150

ORIGINAL ARTICLE

Ahead of Print

LncRNA GAS5 enhances tumor stem cell-like medicated sensitivity of paclitaxel and inhibits epithelial-to-mesenchymal transition by targeting the miR-18a-5p/STK4 pathway in prostate cancer Ting-Ting Lu^1,2, Xia Tao³, Hua-Lei Li⁴, Ling Gai⁵, Hua Huang⁶, Feng Li¹ ¹ Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China ² Department of Pathology, Nantong University Medical School, Nantong 226001, China ³ Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong 226001, China ⁴ Department of Urology, Affiliated Hospital of Nantong University, Nantong 226001, China ⁵ Department of Chemotherapy, Affiliated Hospital of Nantong University, Nantong 226001, China ⁶ Department of Pathology, Affiliated Hospital of Nantong University, Nantong 226001, China Correspondence Address: Feng Li, Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001 China Source of Support: None, Conflict of Interest: None DOI: 10.4103/aja2021117 PMID: 35295003

The onset of prostate cancer (PCa) is often hidden, and recurrence and metastasis are more likely to occur due to chemotherapy resistance. Herein, we identified downregulated long noncoding RNA (lncRNA) growth arrest-specific 5 (GAS5) in PCa that was associated with metastasis and paclitaxel resistance. GAS5 acted as a tumor suppressor in suppressing the proliferation and metastasis of paclitaxel-resistant PCa cells. GAS5 overexpression in vivo inhibited the tumor growth of xenografts and elevated PCa sensitivity to paclitaxel. Combination of GAS5 and paclitaxel treatment showed great potential in PCa treatment. Moreover, mechanistic analysis revealed a novel regulatory network of GAS5/miR-18a-5p/serine/threonine kinase 4 (STK4) that inhibits epithelial-to-mesenchymal transition (EMT) and enhances tumor stem cell-like-mediated sensitivity to paclitaxel in PCa. These findings provide a novel direction for the development of a potential adjunct to cancer chemotherapy that aims to improve the sensitivity of chemotherapy drugs in PCa.


[FULL TEXT] [PDF]

  Search Pubmed for

    -  Lu TT
    -  Tao X
    -  Li HL
    -  Gai L
    -  Huang H
    -  Li F

Citation Manager

Article Access Statistics

Reader Comments

* Requires registration (Free)

Article Access Statistics

Viewed	746

PDF Downloaded	26


Sitemap \| What's New \| Feedback \| Disclaimer \| Privacy Notice This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (http://publicationethics.org/)
© Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine \| Published by Wolters Kluwer - Medknow in association with Editorial office, Asian Journal of Andrology
Online since 1999, New website online since 10 September, 2013